Company Comparison
Forty Seven vs 10x Genomics
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | Forty Seven | 10x Genomics |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | Menlo Park, California | — |
| Founded | 2014 | — |
| Status | Active | Active |
| Last Funding Stage | Series C | — |
| Total Funding | $320M | — |
| Valuation | — | — |
What They Build
Forty Seven
Biotechnology company developing cancer immunotherapies targeting the CD47 pathway to enhance immune system recognition of cancer cells.
10x Genomics
10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics.
Key Investors
Sector Overlap
Both Forty Seven and 10x Genomics operate in Biotech.
Browse all Biotech companies →Websites
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Now in alpha with select funds. 14-day trial available.